The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity
Juhi R. Kuchroo, David A. Hafler, Arlene H. Sharpe, Liliana E. Lucca
Abstract
Immune checkpoint blockade has demonstrated success in treating cancer but can lead to immune-related adverse events (irAEs), illustrating the centrality of these pathways in tolerance. Here, we describe programmed cell death protein 1 (PD-1) control of T cell responses, focusing on its unique restraint of regulatory T cell function. We examine successes and limitations of checkpoint blockade immunotherapy and review clinical and mechanistic features of irAEs. Last, we discuss strategies to modulate PD-1 blockade to enhance antitumor immunity while limiting autoimmunity.
Topics & Concepts
BlockadeAutoimmunityImmune checkpointImmunotherapyImmune systemCancer immunotherapyImmunologyMedicineBiologyReceptorInternal medicineCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionCAR-T cell therapy research